Leerink initiated coverage of Scholar Rock (SRRK) with an Outperform rating and $51 price target The firm notes lead asset apitegromab is in regulatory review as an add-on therapy for spinal muscular atrophy, with September 22nd PDUFA. With 3 approved SMN-targeted therapies as standard of care, apitegromab’s novel MoA offers increased muscle function and mass to counterbalance motor decline seen with approved agents over time. Despite investor nervousness on CDMO concerns ahead of PDUFA, Leerink sees Scholar Rock as one of the most appealing launch stories in its coverage over the next 12-24 months, based on positive channel feedback, flexible regulatory/reimbursement, and the most experienced rare disease commercialization team in its coverage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SRRK:
- Scholar Rock assumed with a Buy at Jefferies
- Scholar Rock publishes SAPPHIRE trial data in The Lancet
- Positive Outlook on Scholar Rock Holdings Due to Innovative Therapies and Strategic Advancements
- Scholar Rock’s Optimistic Earnings Call Highlights Progress
- Scholar Rock Reports Q2 2025 Progress and Financials